Retifanlimab gets knocked back by a US adcom. Could a rival now beat it to become the eighth anti-PD-(L)1 to reach the US market?
Picking up the Lilly cast-off might not have been an easy win for Provention after all.
Just when investors thought they had seen the worst of it, the delayed Fibrogen/Astrazeneca project faces another problem.
The much-heralded Gilead and Galapagos partnership takes a big knock as the US biotech cuts some of its losses with the doomed arthritis project.